Details

Autor(en) / Beteiligte

• Gulick, Roy M
• Ribaudo, Heather J
• Shikuma, Cecilia M
• Lustgarten, Stephanie
• Squires, Kathleen E
• Meyer, William A
• Acosta, Edward P
• Schackman, Bruce R
• Pilcher, Christopher D
• Murphy, Robert L
• Maher, William E
• Witt, Mallory D
• Reichman, Richard C
• Snyder, Sally
• Klingman, Karin L
• Kuritzkes, Daniel R

Titel

Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection

Ist Teil von

• The New England journal of medicine, 2004-04, Vol.350 (18), p.1850-1861

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2004

Quelle

MEDLINE

Beschreibungen/Notizen

• Protease-sparing regimens are often used in the initial treatment of HIV-1 infection. This double-blind trial was stopped after an interim analysis showed poorer virologic responses with the triple-nucleoside-analogue regimen of zidovudine, lamivudine, and abacavir than with regimens containing efavirenz, a nonnucleoside reverse-transcriptase inhibitor, plus two or three nucleoside analogues. An interim analysis showed poorer virologic responses with the triple-nucleoside-analogue regimen. Antiretroviral therapy for human immunodeficiency virus type 1 (HIV-1) infection decreases viremia, increases CD4 cell counts, and delays clinical progression and death. 1 – 5 Current treatment guidelines recommend initial therapy with one or more protease inhibitors or a nonnucleoside reverse-transcriptase inhibitor together with two nucleoside reverse-transcriptase inhibitors. 6 , 7 Though effective, protease-inhibitor–based regimens are complex and have been associated with side effects such as hyperlipidemia and insulin resistance. 8 – 10 Regimens containing nonnucleoside reverse-transcriptase inhibitors are often preferred because of their demonstrated efficacy 11 – 13 and convenience. 14 Triple-nucleoside regimens are an alternative to regimens containing nonnucleoside reverse-transcriptase inhibitors or protease inhibitors. 6 , 7 Triple-nucleoside combinations . . .